Nature Reviews Neuroscience ARTICLE SERIES ON NEURAL CIRCUITS
This article series explores different approaches for the analysis of the structure and function of neural circuits and describes the methodological advances that are driving research in this area.
Four-strain flu vaccines coming to a pharmacy near you doi:10.1038/nm0412-471 The US Food and Drug Administration recently approved MedImmune's FluMist Quadrivalent, the first four-pronged influenza vaccine to contain both B strains, with GlaxoSmithKline, Sanofi-Pasteur and Novartis hoping to follow suit with similar quadrivalent products. Full Text
Amgen swallows Micromet to BiTE into ALL market doi:10.1038/nbt0412-300c Amgen has recently closed a deal with Micromet to acquire not only a cancer immunotherapy based on the bispecific monoclonal antibody fragment blinatumomab but also the underlying 'bispecific T-cell engager' technology that gave rise to it. Full Text
Biotech innovators jump on biosimilars bandwagon doi:10.1038/nbt0412-297a With global sales forecast to rise to as much as $2.6 billion by 2015, biosimilars could become the single fastest-growing biologics sector in the next five years. Full Text
Companies hope for rare win with cancer stem cell therapies doi:10.1038/nm0412-474a Several up-and-coming drugmakers are exploring ways of curtailing cancer stem cells, either through direct inhibition or by forcing the cells to differentiate into run-of-the-mill bulk tumor cells that are susceptible to standard treatments. Full Text
Targeting CDK in triple-negative breast cancer doi:10.1038/scibx.2012.379 Researchers have found that the majority of triple-negative breast cancers have a dysregulated MYC pathway, and shown that cyclin-dependent kinase inhibitors such as Merck and Ligand's dinaciclib could selectively kill off these tumors. The group is planning a clinical trial to test an undisclosed CDK inhibitor in this patient population. Full Text
Fresh from the Pipeline: Aflibercept doi:10.1038/nrd3700 Fusion protein that inhibits vascular endothelial growth factor signalling approved in the United States for the treatment of neovascular age-related macular degeneration. Full Text
From the analyst's couch: Rare diseases and orphan drugs doi:10.1038/nrd3654 This article discusses market trends in the development of drugs for rare diseases, which have increasingly been recognized as providing attractive opportunities for the biopharmaceutical industry. Full Text
Neuromuscular disorders: Troponin activator improves muscle function doi:10.1038/nrd3703 A small-molecule activator of the troponin complex increased skeletal muscle strength in a rodent model of neuromuscular disease. Full Text
Neurological disorders: A class of its own doi:10.1038/nrd3704 A potential new class of drugs offers enhanced selectivity and efficacy over the drugs that are currently used in the clinic to treat absence seizures. Full Text
Immunotherapy: Combinations that work doi:10.1038/nrc3250 Preclinical data support the strategy of combining tumour-targeted therapies with immune-stimulating agents. Full Text
Novel molecular targets for atrial fibrillation therapy doi:10.1038/nrd3682 This Review focuses on the mechanistic rationale for the development of new anti-atrial fibrillation drugs, on the molecular and structural motifs that they target and on the results obtained so far in experimental and clinical studies. Full Text
Combining immunotherapy and targeted therapies in cancer treatment doi:10.1038/nrc3237 This article outlines how combining targeted approaches, which inhibit molecular pathways that promote tumour growth and maintenance, with immunotherapy, which stimulates a host immune response that effectuates long-lived tumour destruction, could provide therapeutic synergy. Full Text
A proteomics approach for the identification and cloning of monoclonal antibodies from serum doi:10.1038/nbt.2167 Cheung et al. couple proteomics with next-generation sequencing of RNA from B cells to clone antibodies directly from the sera of immunized rabbits and mice, potentially advancing immunology and vaccinology research and the development of therapeutics. Full Text
Using virally expressed melanoma cDNA libraries to identify tumor-associated antigens that cure melanoma doi:10.1038/nbt.2157 Pulido et al. identify specific tumor-associated antigens from tumor-derived virus-expressed cDNA libraries that can be used in combination to cure established melanoma in mice. Full Text
Career snapshots archive Career snapshots feature people associated with drug discovery and drug development, with the aim of providing expert insights and advice on a wide range of positions and career paths in this field. Full Text
SciBX: Science-Business eXchange is a weekly publication that identifies and analyzes the most important translational research articles from over 40 journals. Find out which papers have real scientific and commercial potential, and why.
Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com
You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant)
Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA
Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston
Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS.
No comments:
Post a Comment